Charlie Lees is a Professor of Gastroenterology, University of Edinburgh.
From Charlie Lees on X (10/14/26):
Related blog posts:
- Good Tips from Atomic IBD and Charlie Lees
- Over 60% of Initial Nonresponders Improve with Extended Risankizumab Therapy for Crohn’s Disease
- Don’t Rush to Judge Risankizumab Effectiveness for Ulcerative Colitis
Dr. Maria Oliva-Hemker: Positioning Therapies for Pediatric Crohn’s Disease - Comparative Evidence and Positioning Advance Therapies for Inflammatory Bowel Disease
- Risankizumab Outperforms Ustekinumab
- Crohn’s Disease: Risankizumab Real-World Data
- Impressive Results for Risankizumab in Refractory Crohn’s Disease
- Risankizumab Receives FDA Approval for Crohn’s Disease
